An observational study in Sarcoma, sponsored by Institut Bergonié. Recruiting at 3 sites in France. Per ClinicalTrials.gov, last updated 2025-09-04.
Sponsored by Institut Bergonié · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies in Sarcoma by Institut Bergonié — 6 open to participants now, 9 under way, 1 of them phase 3. Sarcoma · Institut Bergonié.
Among the 22 studies in Sarcoma by Institut Bergonié, this one is the only one that started in 2010, is one of 4 observational ones, and was the 12th registered.
1,610 studies on the registry are indexed under Sarcoma; 367 are open to participants now.
Browse Sarcoma studies →6 of the 22 studies in Sarcoma by Institut Bergonié are open now, in 1 country. Recruiting first, the newest first:
Institut Bergonié · Sites in France
Ages 15–49
Institut Bergonié · Sites in France
Ages 18+
Institut Bergonié · Sites in France
Ages 18+
Institut Bergonié · Sites in France
Ages 18+
Institut Bergonié · Sites in France
Ages 18+
By country, each count listing its studies:
Of the 302 Sarcoma studies recruiting now, 192 (64%) set no upper age limit and 83 (27%) stop at 75 or younger; 94 take children under 18; 12 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 11 · Phase 3 1
First in 1990; this study’s year is marked. 1 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 150,000 is above the median of 120 across 220 observational studies indexed under Sarcoma.
Median enrollment 69 across the 18 interventional studies, 1,256 across the 4 observational. Of the 11 that completed or were terminated, 7 (64%) have results posted.
This tab as a report to print or save as PDF → With an account.
Institut Bergonié is the lead sponsor of 119 studies on the registry; 16 are open to participants now.
4 of the studies in Sarcoma by Institut Bergonié that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03805022Phase 3Institut BergoniéBenefit of Intensified Peri-operative Chemotherapy Within High-risk CINSARC Patients With Resectable Soft-tissue Sarcomas | 2026-12 |
| NCT02789384Institut BergoniéCINSARC Signature and Correlation With Hemotherapy Efficacy in Soft-tissue Sarcomas. A Biomarker Study. | 2026-12 |
| NCT05182164Institut BergoniéCombination of Pembrolizumab and Cabozantinib in Patients With Advanced Sarcomas | 2026-12 |
| NCT04874311Institut BergoniéBintrafusp Alfa and Doxorubicin Hydrochloride in Treating Patients With Advanced Sarcoma | 2027-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 22 studies in Sarcoma by Institut Bergonié, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The BCB SARCOMES database is a clinical and biological national database dedicated to sarcoma that contains 3 main databases with specific aims: the first is the pathology database (French expert network dedicated to the management of bone sarcomas [RESOS] / French expert network dedicated to the pathology of sarcomas [RREPS]), dedicated to systematic review of mesenchymal tumor diagnostics nationwide; the second is clinical (RESOS / French expert clinical network for sarcomas [NETSARC]), collecting multidisciplinary tumor boards (MDTB) data of patients nationwide, and the third (CONTICABASE / BONE / GIST) is dedicated to collecting patients longitudinal/follow up data, with a focus on treatments of every events, and a catalogue of associated samples.
Primary objectives of BCB-SARCOMES are the following: description of the patterns of care and treatment outcomes, assessment of the prognostic factors of patients' outcomes.
With the financial support of the French National Cancer Institute [Institut National du cancer [INCa]).
Diagnosis of sarcoma
Inclusion criteria :
Patients with a sarcoma diagnosed in a French Comprehensive cancer Center
Drug: Chemotherapy · Drug: Immunotherapeutic Agent · Drug: target treatment · Procedure: Surgery · Radiation: Radiotherapy
treatment as per standard of care
treatment as per standard of care
treatment as per standard of care
treatment as per standard of care
treatment as per standard of care
Time to next treatment (TNT)
Time from the systemic treatment onset to the next treatment or death due to any cause, whichever comes first. When neither death nor new systemic therapy is observed, TNT is censored at the date of last patient contact.
Time frame: 2 years
Time to next treatment (TNT)
Time from the systemic treatment onset to the next treatment or death due to any cause, whichever comes first. When neither death nor new systemic therapy is observed, TNT is censored at the date of last patient contact.
Time frame: 5 years
Overall survival (OS)
Interval between diagnosis and the time of death. When death is not observed, OS is censored at the date of last patient contact.
Time frame: 2 years
Overall survival (OS)
Interval between diagnosis and the time of death. When death is not observed, OS is censored at the date of last patient contact.
Time frame: 5 years
Plan to share: Undecided
Started Jan 2010 (actual). Primary completion is estimated for Dec 2030, 251 months after the start.
Of 88 non-industry observational studies under Sarcoma, half reached primary completion within 72 months of starting (the median), counting those still running; a quarter within 47 and three quarters within 294. This study's planned 251 months is above that.
Counting every sponsor, half of 97 studies reached it within 66 months; a quarter within 42 and three quarters within 294.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.